期刊论文

Clinical observation on relieving adverse reaction from HAART in HIV/AIDS patients with the Redu Neiyun syndrome with the Aifukang capsule

中文

中医临床研究

1674-7860

2017

9

24

70-72

10.3969/j.issn.1674-7860.2017.24.030

“十二五”国家科技重大专项艾滋病和病毒性肝炎等重大传染病防治（课题编号:2013ZX10005001）；

本校为第一机构

目的：观察艾复康胶囊对于减轻热毒内蕴证型HIV/AIDS患者HAART疗法毒副作用的有效性及安全性,从而提高HAART疗法的依从性和成功率。方法：采用随机、双盲、安慰剂空白对照的临床试验方法,将50例初治HIV/AIDS患者,按1：1的比例分为治疗组和对照组。疗程24周,记录HAART疗法毒副作用发生情况,对治疗前后免疫指标、病毒载量进行数据分析。结果：（1）治疗组毒副发生比率及严重程度优于对照组;（2）免疫指标（CD4＋T细胞计数）：治疗组与对照组治疗后免疫指标均改善,但治疗组优于对照组（P〈0.05）;（3）病毒载量检测：治疗组与对照组治疗后病毒载量均下降（P〉0.05）,两组比较无统计学意义。结论：艾...

Objective： To observe safety and the effect of the Aifukang capsule on adverse reaction from HAART in HIV/AIDS patients, in order to improve the compliance and success rate of HAART. Method： Randomized, double-blind, placebo-controlled clinical approach was applied in this study. 50 case of HIV/AIDS were randomly assigned to the treatment and placebo groups with 1： 1 ratio. The course of treatment lasted for 24 weeks. The occurrence of the adverse events was recorded and the data of viral load and immune indices（CD4 ＋ T cell） before and a...